Medtox' drugs-of-abuse device:
This article was originally published in Clinica
Executive Summary
Medtox Scientific's Sure-Screen drugs-of-abuse point-of-collection test (POCT) device that it believes provides significantly lower detection levels for eight commonly abused drugs, compared with other FDA-cleared POCT product. The Sure-Screen device is designed to provide lower detection levels for marijuana, opiates, cocaine, amphetamines, methadone, benzodiazepines, methamphetamines and MDMA-Ecstasy by an average of around 50% each. The St Paul, Minnesota company believes that much lower detection levels will be in demand in markets interested in "zero tolerance".
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.